The US regulator has cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade ... could be peak sales of around $5 billion for the drug. Near-term readouts include ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback